Table 18.8 Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival	(Percent)								
Year of Diagnosis:	(ICICCIIC)								
1960-1963 ^a		_	-	12	13	10	-	_	_
1970-1973 ^a		_	-	19	20	17		_	_
						24.7			
1975-1977 ^b	24.6	23.9	25.3	24.1	23.6		29.3	28.9	29.5
1978-1980 ^b	25.9	24.4	27.5	24.8	24.1	25.5	32.5	27.4	37.5
1981-1983 ^b	27.5	25.7	29.4	27.2	25.4	28.9	28.9	29.6	27.9
1984-1986 ^b	27.3	27.7	26.8	26.0	25.8	26.2	31.8	33.3	30.3
1987-1989 ^b	27.2	28.8	25.6	26.8	29.1	24.5	30.0	29.3	30.6
1990-1992 ^b	29.3	30.6	27.9	28.4	29.7	26.9	34.2	38.0	30.6
1993-1995 ^b	31.7	32.3	31.0	30.5	31.4	29.5	35.4	34.9	35.7
1996-1998 ^b	32.5	34.5	30.4	32.3	34.4	29.9	31.6	32.9	30.6
1999-2001 ^b	34.6	37.0	31.9	34.5	37.0	31.5	34.4	37.2	32.0
2002-2004 ^b	42.6	43.6	41.4	43.4	44.8	41.6	40.7	40.8	40.7
2002-2004 2005-2008 ^b	47.5	47.8	47.1	47.1	48.3	45.4	40.7	45.8	52.7
	47.5 53.7 ^f	47.0 54.4 ^f	47.1 52.9 ^f			45.4 52.0 ^f	49.5 55.1 ^f	45.0 54.8 ^f	52.7
2009-2015 ^b	53./-	54.4-	52.9-	53.2 ^f	54.1 ^f	52.0-	55.1-	54.8-	55.4
-Year Period Survival (P	Percent) ^{cd}								
2015	53.0	52.5	53.6	51.8	51.3	52.4	55.0	54.6	55.4
Stage Distribution (%) 20	00-2015 ^{ce}								
All Stages	09-2015								
	24 220	10 005	1 5 2 2 5	24 646	14 000	10 557	C 02C	2 2 4	2 572
Number of cases	34,220	18,885	15,335	24,646	14,089	10,557	6,936	3,364	3,572
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	5	4	5	6	5	4	4	3
Regional	0	0	0	0	0	0	0	0	0
Distant	95	95	96	95	94	95	96	96	97
Unstaged/Unknown	0	0	0	0	0	0	0	0	0
5-Year Relative Survival	(Percent), 2	009-2015°							
Age at Diagnosis:	(10100110))) 1	2010							
Ages <45	76.2	74.2	79.3	76.6	75.1	79.1	73.4	69.3	78.1
5	66.2	64.5	68.4	66.4	64.7	68.7	65.4	63.2	67.4
Ages 45-54	60.2	58.7	62.3	60.4	59.7	62.4	58.3	55.2	61.3
Ages 55-64									
Ages 65-74	53.4	52.9	54.0	53.2	52.1	54.8	52.3	53.7	50.9
Ages 75+	32.9	33.1	32.8	32.2	32.5	31.8	34.1	32.9	34.8
Ages <65	63.6	62.0	65.8	63.9	62.6	65.8	62.2	59.3	65.1
Ages 65+	43.5	44.0	43.0	42.8	43.0	42.5	44.6	46.1	43.5
Stage ^e :									
All Stages	52.2	52.1	52.4	51.3	51.3	51.3	53.9	53.4	54.4
Localized	73.9	73.7	73.9	73.9	74.0	73.6	71.4	71.0 ^g	71.5
Regional	-	-	-	-	-	-	-	-	-
Distant	51.1	50.8	51.4	50.1	50.0	50.2	53.2	52.6	53.8
Unstaged/Unknown		_							

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2016. Expected survival rates are derived from the U.S. Annual Life Tables. SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2016.

Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),

(2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2009-2015 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.

b

С

d

e

f

g

h

_